Cidara Therapeutics, Inc. CDTX
Set alert
As of Jan 8, 9:30 AM ET
- YTD
- +0.22%
- 1 year
- +725.74%
- Open
- 221.38
- Prev close
- 221.38
- Mkt cap
- 5.61B
- Vol
- 2.69M
- Avg vol
- 919.35K
- EPS
- -11.78
- P/E
- -46.61
- Div yield
- 0.00%
More statistics
- Low
- 221.38
- High
- 221.38
- Beta
- 1.53
- Inst. own
- 103.89%
- Dividend
- 0.00
1M chart
Signals (7)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Dec 30, 2025 | 10 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| SMA: Bullish | Dec 17, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bullish | Dec 11, 2025 | 10 months ago |
| SMA: Bearish | Dec 10, 2025 | 10 months ago |
| SMA: Bullish | Dec 9, 2025 | 10 months ago |
Key statistics
- Market cap
- 5.61B
- Enterprise value
- 5.32B
- Trailing P/E
- -46.61
- PEG ratio
- -1.58
- Price / sales
- 0.00
- Price / book
- 8.15
- Beta
- 1.53
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- -23.59%
Analyst view
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.33.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2025 | Sep 30, 2025 | -1.34 | -3.10 | -1.76 | -131.34% |
| Aug 7, 2025 | Jun 30, 2025 | -1.87 | -1.65 | +0.22 | +11.76% |
| May 8, 2025 | Mar 31, 2025 | -5.45 | -1.66 | +3.79 | +69.54% |
| Mar 6, 2025 | Dec 31, 2024 | -5.28 | -5.38 | -0.10 | -1.89% |
| Nov 7, 2024 | Sep 30, 2024 | -5.22 | -2.38 | +2.84 | +54.41% |
| Aug 13, 2024 | Jun 30, 2024 | -3.94 | -19.99 | -16.05 | -407.36% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2025 | Guggenheim | down | Buy | Neutral |
| Nov 14, 2025 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 14, 2025 | Needham | down | Buy | Hold |
| Nov 7, 2025 | RBC Capital | main | Outperform | Outperform |
| Nov 7, 2025 | Needham | main | Buy | Buy |
| Oct 21, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
About Cidara Therapeutics, Inc.
Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 38
- Website
- msd.platform-apps.io
News
- Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?
- Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
- Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight
- 3,187 Shares in Cidara Therapeutics, Inc. $CDTX Bought by ANB Bank
- Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of “Hold” from Analysts
- Is Cidara Therapeutics a Buy After HighVista Strategies Initiated a Position in the Stock?
- Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Hold” from Brokerages
- 3 Potential Mid-Cap Biotech Buyout Targets In 2026
- Geode Capital Management LLC Grows Stock Position in Cidara Therapeutics, Inc. $CDTX
- Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their Rights
Your note
Sign in to keep a note on CDTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAVARPANAH NICOLE NEGAR | Officer | Stock Gift | Dec 28, 2025 | 20,886 |
| KARBE FRANK L | Chief Financial Officer | Stock Award(Grant) | Feb 23, 2025 | 57,500 |
| MINEO CHRYSA | Director | Purchase | Jun 2, 2025 | 3,320 |
| RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Jun 25, 2025 | 0 |
| SANDISON TAYLOR | Officer | Sale | Sep 10, 2024 | 23,067 |
| SHAH PREETAM | Chief Financial Officer | Stock Award(Grant) | Mar 14, 2024 | 335,960 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, LLC | 13.27% | 3,365,523 | 0 | Jun 29, 2025 |
| Bain Capital Life Sciences Investors, LLC | 9.86% | 2,500,680 | 0 | Jun 29, 2025 |
| Point72 Asset Management, L.P. | 6.03% | 1,527,930 | 0 | Jun 29, 2025 |
| Vivo Capital, LLC | 5.17% | 1,311,425 | 0 | Jun 29, 2025 |
| COMMODORE CAPITAL LP | 4.63% | 1,175,000 | 0 | Jun 29, 2025 |
| BlackRock Inc | 4.37% | 1,107,668 | 0 | Jun 29, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.34% | 592,283 | 0 | Jul 30, 2025 |
| iShares Russell 2000 ETF | 1.59% | 404,282 | 0 | Aug 30, 2025 |
| abrdn Healthcare Investors | 0.71% | 179,902 | 0 | Aug 30, 2025 |
| Fidelity Small Cap Index | 0.66% | 168,540 | 0 | Jun 29, 2025 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.63% | 159,673 | 0 | Jul 30, 2025 |
| iShares Russell 2000 Value ETF | 0.58% | 147,778 | 0 | Aug 30, 2025 |